Jennifer L. Alejo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jennifer L. Alejo has a total of 153 co-authors. Here are the top co-authors by number of shared publications:
- Dorry Lidor Segev
Department of Surgery New York University New York New York USA
22 shared publications - William A. Werbel
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
19 shared publications - Teresa Po-Yu Chiang
Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
13 shared publications - Aaron A. R. Tobian
Department of Pathology Johns Hopkins University School of Medicine Baltimore Maryland USA
12 shared publications - Allan B. Massie
Department of Surgery, New York University Langone Transplant Institute, New York, USA
12 shared publications - Aura T. Abedon
Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA
11 shared publications
Latest Publications
- 2 July 2024
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 79 (3) , 652-655
Rapid Wane and Recovery of XBB Sublineage Neutralization After Sequential Omicron-based Vaccination in Solid Organ Transplant Recipients
Durability of variant neutralization in solid organ transplant recipients following Omicron-containing boosters is unknown. We report wane in XBB.1.5 neutralization by 3 months following a first bivalent booster, improved by a second booster; hybrid immunity improved peak, and duration of neutralization. Boosting at 3 to 6 months appears necessary to maintain neutralization.
- 2 July 2024
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 79 (3) , 652-655
Rapid Wane and Recovery of XBB Sublineage Neutralization After Sequential Omicron-based Vaccination in Solid Organ Transplant Recipients
Durability of variant neutralization in solid organ transplant recipients following Omicron-containing boosters is unknown. We report wane in XBB.1.5 neutralization by 3 months following a first bivalent booster, improved by a second booster; hybrid immunity improved peak, and duration of neutralization. Boosting at 3 to 6 months appears necessary to maintain neutralization.
- Open Access
- 1 July 2024
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 51 (9) , 928-933
Prevalence and Risk Factors of Postacute Sequelae of COVID-19 in Adults With Systemic Autoimmune Rheumatic Diseases
Objective: Incidence and manifestations of postacute sequelae of coronavirus disease 2019 (PASC) are poorly defined among immunosuppressed populations. We reported, phenotyped, and assessed risk factors for PASC in adults with systemic autoimmune diseases.Methods: Persons aged ≥ 18 years with systemic autoimmune diseases were recruited into a national, prospective observational cohort of SARS-CoV-2 vaccination and infection between December 2020 and April 2021. Serial surveys assessed vaccination status, SARS-CoV-2 infection incidence, and disease flares. Participants reporting SARS-CoV-2 infection received a questionnaire assessing symptom duration, severity, and quality of life (QOL) effect; PASC was defined as ≥ 1 symptom persisting for > 12 weeks. PASC syndromes were mapped by overlapping symptom domains. Characteristics were compared between participants who did vs did not report PASC.Results: Among 1615 participants, 590 (36.5%) reported SARS-CoV-2 infection and were sent PASC surveys, 299 (50.7%) of whom responded > 12 weeks following the reported infection. Respondents were 91.6% female, 91.2% White, median (IQR) age was 48 (40-60) years with median (IQR) 3 (2-3) vaccine doses at time of first infection. Common diagnoses included inflammatory arthritis (38.5%) and inflammatory bowel disease (14.4%). Eighty-nine of 299 (29.8%) reported PASC, with the most reported symptom domain being neurological/psychological (83.1%); 84% reported an effect on QOL. Participants with PASC reported lower number of preceding vaccines (median [IQR] 2 [2-3] vs 3 [2-3];P< 0.001) and more reinfections (16.9% vs 5.7%;P= 0.004).Conclusion: In a large, real-world cohort, 29.8% of persons with systemic autoimmune disease reported PASC, often affecting QOL. Preceding vaccination may reduce PASC, whereas multiple infections may increase risk, supporting ongoing booster vaccine campaigns and efforts to limit breakthrough infections.
- 1 July 2024
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 51 (9) , 928-933
Open AccessPrevalence and Risk Factors of Postacute Sequelae of COVID-19 in Adults With Systemic Autoimmune Rheumatic Diseases
Objective: Incidence and manifestations of postacute sequelae of coronavirus disease 2019 (PASC) are poorly defined among immunosuppressed populations. We reported, phenotyped, and assessed risk factors for PASC in adults with systemic autoimmune diseases.Methods: Persons aged ≥ 18 years with systemic autoimmune diseases were recruited into a national, prospective observational cohort of SARS-CoV-2 vaccination and infection between December 2020 and April 2021. Serial surveys assessed vaccination status, SARS-CoV-2 infection incidence, and disease flares. Participants reporting SARS-CoV-2 infection received a questionnaire assessing symptom duration, severity, and quality of life (QOL) effect; PASC was defined as ≥ 1 symptom persisting for > 12 weeks. PASC syndromes were mapped by overlapping symptom domains. Characteristics were compared between participants who did vs did not report PASC.Results: Among 1615 participants, 590 (36.5%) reported SARS-CoV-2 infection and were sent PASC surveys, 299 (50.7%) of whom responded > 12 weeks following the reported infection. Respondents were 91.6% female, 91.2% White, median (IQR) age was 48 (40-60) years with median (IQR) 3 (2-3) vaccine doses at time of first infection. Common diagnoses included inflammatory arthritis (38.5%) and inflammatory bowel disease (14.4%). Eighty-nine of 299 (29.8%) reported PASC, with the most reported symptom domain being neurological/psychological (83.1%); 84% reported an effect on QOL. Participants with PASC reported lower number of preceding vaccines (median [IQR] 2 [2-3] vs 3 [2-3];P< 0.001) and more reinfections (16.9% vs 5.7%;P= 0.004).Conclusion: In a large, real-world cohort, 29.8% of persons with systemic autoimmune disease reported PASC, often affecting QOL. Preceding vaccination may reduce PASC, whereas multiple infections may increase risk, supporting ongoing booster vaccine campaigns and efforts to limit breakthrough infections.
- Open Access
- 19 January 2024
- Published by Wiley in Clinical Transplantation
- Vol. 38 (1) , e15233
Letter to the editor: Poor sensitivity of anti‐nucleocapsid antibody in detecting prior COVID‐19 in vaccinated solid organ transplant recipients
- 19 January 2024
- Published by Wiley in Clinical Transplantation
- Vol. 38 (1) , e15233
Open AccessLetter to the editor: Poor sensitivity of anti‐nucleocapsid antibody in detecting prior COVID‐19 in vaccinated solid organ transplant recipients
- Open Access
- 17 June 2023
- Published by Wiley in Clinical Transplantation
- Vol. 37 (8) , e15044
Letter to the editor: “hook” (prozone) effect in sars‐cov‐2 anti‐spike binding antibody levels following vaccination, infection, or monoclonal antibody in solid organ transplant recipients
- 17 June 2023
- Published by Wiley in Clinical Transplantation
- Vol. 37 (8) , e15044
Open AccessLetter to the editor: “hook” (prozone) effect in sars‐cov‐2 anti‐spike binding antibody levels following vaccination, infection, or monoclonal antibody in solid organ transplant recipients
- Open Access
- 22 May 2023
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 8 (10)
Heterologous versus homologous boosting elicits qualitatively distinct, BA.5–cross-reactive T cells in transplant recipients
Background: The SARS-CoV-2 Omicron BA.5 subvariant escapes vaccination-induced neutralizing antibodies because of mutations in the spike (S) protein. Solid organ transplant recipients (SOTRs) develop high COVID-19 morbidity and poor Omicron variant recognition after COVID-19 vaccination. T cell responses may provide a second line of defense. Therefore, understanding which vaccine regimens induce robust, conserved T cell responses is critical. Methods: We evaluated anti-S IgG titers, subvariant pseudo-neutralization, and S-specific CD4 + and CD8 + T cell responses from SOTRs in a national, prospective, observational trial ( n = 75). Participants were selected if they received 3 doses of mRNA (homologous boosting) or 2 doses of mRNA followed by Ad26.COV2.S (heterologous boosting). Results: Homologous boosting with 3 mRNA doses induced the highest anti-S IgG titers. However, antibodies induced by both vaccine regimens demonstrated lower pseudo-neutralization against BA.5 compared with the ancestral strain. In contrast, vaccine-induced S-specific T cells maintained cross-reactivity against BA.5 compared with ancestral recognition. Homologous boosting induced higher frequencies of activated polyfunctional CD4 + T cell responses, with polyfunctional IL-21 + peripheral T follicular helper cells increased in mRNA-1273 compared with BNT162b2. IL-21 + cells correlated with antibody titers. Heterologous boosting with Ad26.COV2.S did not increase CD8 + responses compared to homologous boosting. Conclusion: Boosting with the ancestral strain can induce cross-reactive T cell responses against emerging variants in SOTRs, but alternative vaccine strategies are required to induce robust CD8 + T cell responses. Funding: Ben-Dov Family; NIH National Institute of Allergy and Infectious Diseases (NIAID) K24AI144954, NIAID K08AI156021, NIAID K23AI157893, NIAID U01AI138897, National Institute of Diabetes and Digestive and Kidney Diseases T32DK007713, and National Cancer Institute 1U54CA260492; Johns Hopkins Vice Dean of Research Support for COVID-19 Research in Immunopathogenesis; and Emory COVID-19 research repository.
- 22 May 2023
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 8 (10)
Open AccessHeterologous versus homologous boosting elicits qualitatively distinct, BA.5–cross-reactive T cells in transplant recipients
Background: The SARS-CoV-2 Omicron BA.5 subvariant escapes vaccination-induced neutralizing antibodies because of mutations in the spike (S) protein. Solid organ transplant recipients (SOTRs) develop high COVID-19 morbidity and poor Omicron variant recognition after COVID-19 vaccination. T cell responses may provide a second line of defense. Therefore, understanding which vaccine regimens induce robust, conserved T cell responses is critical. Methods: We evaluated anti-S IgG titers, subvariant pseudo-neutralization, and S-specific CD4 + and CD8 + T cell responses from SOTRs in a national, prospective, observational trial ( n = 75). Participants were selected if they received 3 doses of mRNA (homologous boosting) or 2 doses of mRNA followed by Ad26.COV2.S (heterologous boosting). Results: Homologous boosting with 3 mRNA doses induced the highest anti-S IgG titers. However, antibodies induced by both vaccine regimens demonstrated lower pseudo-neutralization against BA.5 compared with the ancestral strain. In contrast, vaccine-induced S-specific T cells maintained cross-reactivity against BA.5 compared with ancestral recognition. Homologous boosting induced higher frequencies of activated polyfunctional CD4 + T cell responses, with polyfunctional IL-21 + peripheral T follicular helper cells increased in mRNA-1273 compared with BNT162b2. IL-21 + cells correlated with antibody titers. Heterologous boosting with Ad26.COV2.S did not increase CD8 + responses compared to homologous boosting. Conclusion: Boosting with the ancestral strain can induce cross-reactive T cell responses against emerging variants in SOTRs, but alternative vaccine strategies are required to induce robust CD8 + T cell responses. Funding: Ben-Dov Family; NIH National Institute of Allergy and Infectious Diseases (NIAID) K24AI144954, NIAID K08AI156021, NIAID K23AI157893, NIAID U01AI138897, National Institute of Diabetes and Digestive and Kidney Diseases T32DK007713, and National Cancer Institute 1U54CA260492; Johns Hopkins Vice Dean of Research Support for COVID-19 Research in Immunopathogenesis; and Emory COVID-19 research repository.
- Open Access
- 1 February 2023
- Published by Wiley in Clinical Transplantation
- Vol. 37 (4) , e14913
Patient‐reported outcomes after Tixagevimab and Cilgavimab pre‐exposure prophylaxis among solid organ transplant recipients: Safety, effectiveness, and perceptions of risk
Background: Tixagevimab and Cilgavimab (T + C) is authorized for pre‐exposure prophylaxis (PrEP) against Coronavirus Disease 2019 (COVID‐19) in solid organ transplant recipients (SOTRs), yet patient‐reported outcomes after injection are not well described. Furthermore, changes in risk tolerance after T + C PrEP have not been reported, of interest given uncertain activity against emerging Omicron sublineages.Methods: Within a national prospective observational study, SOTRs who reported receiving T + C were surveyed for 3 months to ascertain: (1) local and systemic reactogenicity, (2) severe adverse events with focus on cardiovascular and alloimmune complications, and (3) breakthrough COVID‐19, contextualized through (4) changes in attitudes regarding COVID‐19 risk and behaviors.Results: At 7 days postinjection, the most common reactions were mild fatigue (29%), headache (20%), and pain at injection sites (18%). Severe adverse events were uncommon; over 3 months of follow‐up, 4/392 (1%) reported acute rejection and one (.3%) reported a myocardial infarction. Breakthrough COVID‐19 occurred in 9%, 16–129 days after receiving full dose (300/300 mg) T + C, including two non‐ICU hospitalizations. Most surveyed SOTRs (65%) felt T + C PrEP was likely to reduce their COVID‐19 risk, and 70% reported increased willingness to engage in social activities such as visiting friends. However, few felt safe to return to in‐person work (20%) or cease public mask‐wearing (15%).Conclusions: In this prospective study of patient‐reported outcomes, T + C was well tolerated with few serious events. Several COVID‐19 breakthroughs were reported, notable as most SOTRs reported changes in risk tolerance after T + C. These results aid counseling of SOTRs regarding real‐world safety and effectiveness of T + C.
- 1 February 2023
- Published by Wiley in Clinical Transplantation
- Vol. 37 (4) , e14913
Open AccessPatient‐reported outcomes after Tixagevimab and Cilgavimab pre‐exposure prophylaxis among solid organ transplant recipients: Safety, effectiveness, and perceptions of risk
Background: Tixagevimab and Cilgavimab (T + C) is authorized for pre‐exposure prophylaxis (PrEP) against Coronavirus Disease 2019 (COVID‐19) in solid organ transplant recipients (SOTRs), yet patient‐reported outcomes after injection are not well described. Furthermore, changes in risk tolerance after T + C PrEP have not been reported, of interest given uncertain activity against emerging Omicron sublineages.Methods: Within a national prospective observational study, SOTRs who reported receiving T + C were surveyed for 3 months to ascertain: (1) local and systemic reactogenicity, (2) severe adverse events with focus on cardiovascular and alloimmune complications, and (3) breakthrough COVID‐19, contextualized through (4) changes in attitudes regarding COVID‐19 risk and behaviors.Results: At 7 days postinjection, the most common reactions were mild fatigue (29%), headache (20%), and pain at injection sites (18%). Severe adverse events were uncommon; over 3 months of follow‐up, 4/392 (1%) reported acute rejection and one (.3%) reported a myocardial infarction. Breakthrough COVID‐19 occurred in 9%, 16–129 days after receiving full dose (300/300 mg) T + C, including two non‐ICU hospitalizations. Most surveyed SOTRs (65%) felt T + C PrEP was likely to reduce their COVID‐19 risk, and 70% reported increased willingness to engage in social activities such as visiting friends. However, few felt safe to return to in‐person work (20%) or cease public mask‐wearing (15%).Conclusions: In this prospective study of patient‐reported outcomes, T + C was well tolerated with few serious events. Several COVID‐19 breakthroughs were reported, notable as most SOTRs reported changes in risk tolerance after T + C. These results aid counseling of SOTRs regarding real‐world safety and effectiveness of T + C.
- Open Access
- 12 January 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 23 (3) , 423-428
Neutralizing activity and 3-month durability of tixagevimab and cilgavimab prophylaxis against Omicron sublineages in transplant recipients
- 12 January 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 23 (3) , 423-428
Open AccessNeutralizing activity and 3-month durability of tixagevimab and cilgavimab prophylaxis against Omicron sublineages in transplant recipients
- Open Access
- 12 January 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (12) , 3137-3142
mTOR inhibitors, mycophenolates, and other immunosuppression regimens on antibody response to SARS-CoV-2 mRNA vaccines in solid organ transplant recipients
- 12 January 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (12) , 3137-3142
Open AccessmTOR inhibitors, mycophenolates, and other immunosuppression regimens on antibody response to SARS-CoV-2 mRNA vaccines in solid organ transplant recipients
- Open Access
- 30 December 2022
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (9) , 2254-2260
Heterologous Ad.26.COV2.S versus homologous BNT162b2/mRNA-1273 as a third dose in solid organ transplant recipients seronegative after two-dose mRNA vaccination
- 30 December 2022
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (9) , 2254-2260
Open AccessHeterologous Ad.26.COV2.S versus homologous BNT162b2/mRNA-1273 as a third dose in solid organ transplant recipients seronegative after two-dose mRNA vaccination
- 7 December 2022
- Published by Wiley in Clinical Transplantation
- Vol. 37 (1) , e14868
6‐month antibody kinetics and durability after four doses of a SARS‐CoV‐2 vaccine in solid organ transplant recipients
- 7 December 2022
- Published by Wiley in Clinical Transplantation
- Vol. 37 (1) , e14868
6‐month antibody kinetics and durability after four doses of a SARS‐CoV‐2 vaccine in solid organ transplant recipients